Core Viewpoint - Fangzhou Inc. reported a profitable first half of 2025, driven by an expanding user base, improved operating efficiency, and accelerated AI deployment in healthcare services and internal operations [1] Financial Performance - Revenue for the first half of 2025 reached RMB 1.494 billion, marking a 12.9% increase year-on-year [2] - Net profit was RMB 12.5 million, a significant turnaround from a loss of RMB 818.7 million in the same period last year [2] - Adjusted net profit increased by 16.8% to RMB 17.6 million, achieving a new high [2] User Growth - Registered users on the platform grew by 15.8% year-on-year to 52.8 million [3] - Monthly active users surged by 34.4% to 11.9 million [3] - The number of registered doctors increased to 229,000, with a paid user repurchase rate of 85.4%, indicating strong user retention [3] Revenue Breakdown - Revenue from online retail pharmacy services rose by 28.2% to RMB 864 million [4] - Revenue from medical services increased by 11.4% to RMB 357 million [4] - The drug catalog expanded to 215,000 SKUs, with prescription medicines making up approximately 62% [4] Product Innovation - The company launched several innovative drugs through its platform from leading pharmaceutical companies, including Novo Nordisk and Novartis AG [5] AI Integration - Fangzhou accelerated the implementation of AI across various functions, enhancing user services, procurement, marketing, and content production [6] - The upgraded "AI+H2H" platform supports immediate health consultations and long-term disease management, with AI tools assisting doctors and patients [7] - Internally, AI tools were deployed for procurement and content creation, improving operational efficiency [8] Strategic Expansion - The company is enhancing integration with China's national medical insurance system, improving service capabilities for insured patients [9] - Future plans include a "technology innovation + digital integration" strategy, focusing on deeper AI integration and collaboration with drugmakers and health institutions [10] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [11]

Group 1 - The company reported a total revenue of 1.494 billion, representing a year-on-year growth of 12.9% for the first half of 2025 [1] - The company achieved a net profit of 12.5 million, marking a turnaround from losses, while adjusted net profit reached a record high of 17.6 million, up 16.8% year-on-year [1] - Online retail pharmacy service revenue significantly increased to 864 million, a growth of 28.2% year-on-year, while comprehensive medical service revenue reached 357 million, growing by 11.4% [1] Group 2 - The company enhanced its technology foundation by upgrading the "H2H (Hospital to Home) smart medical ecosystem service platform," improving doctor efficiency and user service quality [1] - As of June 30, 2025, the platform had 52.8 million registered users, a steady growth of 15.8% year-on-year, and the number of registered doctors increased to 229,000 [1] - Monthly active users surged by 34.4% year-on-year to 11.9 million, with a high user retention rate, as the repurchase rate for paying users improved to 85.4% [1] Group 3 - The company expanded its drug SKU to 216,000, with approximately 62% being prescription drugs, and established partnerships with over 1,650 suppliers and more than 980 pharmaceutical companies [2] - The company integrated advanced AI capabilities into its operations, completing the "AI+H2H" technology upgrade to create a comprehensive AI application matrix covering user services, supply chain, and content production [2] - The integration of innovative tools with internet healthcare scenarios effectively meets both immediate health consultation and long-term health management needs, enhancing user stickiness and accelerating long-term growth value [2]

Core Insights - The company reported a total revenue of 1.494 billion, representing a year-on-year growth of 12.9% for the first half of 2025 [1] - The company achieved a net profit of 12.5 million, marking a turnaround from losses, while adjusted net profit reached a record high of 17.6 million, up 16.8% year-on-year [1] Business Performance - Online retail pharmacy service revenue reached 864 million, showing a significant increase of 28.2% year-on-year [1] - Comprehensive medical service revenue amounted to 357 million, reflecting a growth of 11.4% year-on-year [1] User Growth and Engagement - As of June 30, 2025, the platform had 52.8 million registered users, achieving a steady growth of 15.8% year-on-year [1] - The number of registered doctors on the platform increased to 229,000, supported by the expansion of the service network [1] - Monthly active users surged by 34.4% year-on-year, reaching 11.9 million, with a high user retention rate as the paid user repurchase rate rose to 85.4% [1] Technological Advancements - The company expanded its drug SKU to 216,000, with approximately 62% being prescription drugs, and established partnerships with over 1,650 suppliers and 980 pharmaceutical companies [2] - The company integrated advanced AI capabilities into its "AI+H2H" technology upgrade, creating a comprehensive AI application matrix that addresses both immediate health consultations and long-term health management needs [2]

Group 1 - The company reported a total revenue of 1.494 billion, representing a year-on-year growth of 12.9% for the first half of 2025 [1] - The net profit turned positive, reaching 12.5 million, while the adjusted net profit hit a new high of 17.6 million, up 16.8% year-on-year [1] - Online retail pharmacy service revenue significantly increased to 864 million, a growth of 28.2% year-on-year, while comprehensive medical service revenue reached 357 million, growing by 11.4% [1] Group 2 - As of June 30, 2025, the platform had 52.8 million registered users, reflecting a steady growth of 15.8% year-on-year, and the number of registered doctors increased to 229,000 [1] - Monthly active users surged by 34.4% year-on-year to 11.9 million, with a high user retention rate, as the repurchase rate for paying users rose to 85.4% [1] - The company expanded its drug SKU to 216,000, with approximately 62% being prescription drugs, and established partnerships with over 1,650 suppliers and 980 pharmaceutical companies [2] Group 3 - The company integrated advanced AI capabilities into its services, completing the "AI+H2H" technology upgrade, which enhances user service, supply chain, and content production [2] - The integration of innovative tools with internet healthcare scenarios allows for precise and efficient responses to both immediate health consultations and long-term health management needs [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 截 至2025年6月30日止六個月的 中期業績公告 董事會欣然公佈本集團截至2025年6月30日止六個月的未經審核簡明 綜合中期業績，連同2024年同期的比較數字如下。該等中期業績已由 審核委員會及本公司核數師畢馬威會計師事務所審閱。 於本公告中，「我們」指本公司，倘文義另有所指，則指本集團。本公告 所載若干金額及百分比數字已經約整，或約整至小數點後一位或兩位 數。任何表格、圖表或其他地方所列總額與當中所列各數字總和之間 的差異乃因約整所致。 – 1 – 此job內 文size和heading size 已加大2pt，leading不 變 此job內 文size和heading size 已加大2pt，leading不 變 財務及業務亮點 我們在2025年上半年的強勁財務業績，反映出我們戰略規劃的堅 ...

Core Viewpoint - The National Computer Virus Emergency Response Center has identified 70 mobile applications that illegally collect and use personal information, highlighting ongoing concerns regarding data privacy and compliance with Chinese laws [1] Company Summary - The application "Ark Health Online Pharmacy" (version 6.42.0, OPPO software store) has been flagged for multiple violations, including failure to inform users about the transfer of their personal information to other parties and not providing a convenient way to withdraw consent for data collection [1] - Ark Health Online Pharmacy is operated by Guangzhou Ark Pharmaceutical Co., Ltd., which is a wholly-owned subsidiary of Guangzhou Ark Cloud Health Information Technology Group Co., Ltd. [1] - Established in 2015, Ark Health focuses on internet-based chronic disease management services and aims to become the largest chronic disease service platform in China [1]

Key Points - The top three stocks with net inflows from southbound funds are China Life (02628) with 1.58 billion, Southern Hang Seng Technology (03033) with 768 million, and Alibaba-W (09988) with 452 million [1][2] - The top three stocks with net outflows are Tencent Holdings (00700) with -1.20 billion, Anta Sports (02020) with -697 million, and Rongchang Biopharmaceutical (09995) with -584 million [1][2] - In terms of net inflow ratio, Datang Renewable (01798) leads with 74.45%, followed by Shenzhen Expressway (00548) with 50.53%, and Bosideng (03998) with 50.23% [1][3] - The top three stocks with the highest net outflow ratios are Chongqing Rural Commercial Bank (03618) at -58.46%, Kington Services (09666) at -54.34%, and Poly Property Group (00119) at -51.88% [1][3] Net Inflow Rankings - The top ten stocks by net inflow include: - China Life (02628): 1.58 billion, 34.91% increase, closing price 23.620 (+3.60%) [2] - Southern Hang Seng Technology (03033): 768 million, 14.65% increase, closing price 5.475 (-0.90%) [2] - Alibaba-W (09988): 452 million, 4.38% increase, closing price 121.800 (-1.54%) [2] - Other notable stocks include Li Auto-W (02015) with 349 million and AIA Group (01299) with 317 million [2] Net Outflow Rankings - The top ten stocks by net outflow include: - Tencent Holdings (00700): -1.20 billion, -5.56% decrease, closing price 590.000 (+0.68%) [2] - Anta Sports (02020): -697 million, -40.49% decrease, closing price 92.450 (+2.72%) [2] - Rongchang Biopharmaceutical (09995): -584 million, -33.65% decrease, closing price 77.450 (+13.65%) [2] - Other notable stocks include Meituan-W (03690) with -387 million and China Construction Bank (00939) with -366 million [2] Net Inflow Ratio Rankings - The top stocks by net inflow ratio include: - Datang Renewable (01798): 74.45%, net inflow of 14.5175 million, closing price 2.360 (+0.85%) [3] - Shenzhen Expressway (00548): 50.53%, net inflow of 8.719 million, closing price 7.020 (0.00%) [3] - Bosideng (03998): 50.23%, net inflow of 6.728 million, closing price 4.630 (+0.65%) [3]

Core Viewpoint - Ark Health (06086) experienced a nearly 10% intraday increase, closing up 8.64% at HKD 3.9, with a trading volume of HKD 66.72 million, following the announcement of a strategic cooperation memorandum with global biopharmaceutical leader Novo Nordisk [1] Group 1 - Ark Health, as a leading AI and internet healthcare company, aims to establish a comprehensive health management service loop covering medication guidance, reminders, effect tracking, and health education [1] - The collaboration is focused on transforming diabetes and obesity management from a "disease-centered" approach to a "health-centered" model, providing patients with higher quality and more convenient one-stop services [1] - The strategic partnership is expected to create a new ecological value chain in the field of glycemic control and weight loss [1]

Core Viewpoint - Ark Health (06086) experienced a nearly 10% intraday increase, closing up 8.64% at HKD 3.9, with a trading volume of HKD 66.72 million, following the announcement of a strategic cooperation memorandum with Novo Nordisk, a global leader in biopharmaceuticals [1] Group 1 - Ark Health, as a leading AI and internet healthcare company, aims to establish a comprehensive health management service loop covering medication guidance, reminders, effect tracking, and health education [1] - The collaboration with Novo Nordisk is expected to create a new ecological value chain in the fields of diabetes and obesity, shifting the focus from "disease-centered" to "health-centered" approaches [1] - The initiative is designed to provide patients with higher quality and more convenient one-stop services [1]

Core Viewpoint - Ark Health (06086) has seen a significant stock increase of 8.64% to HKD 3.9, with a trading volume of HKD 66.72 million, following the announcement of a strategic cooperation memorandum with Novo Nordisk, a global leader in biopharmaceuticals [1] Group 1 - Ark Health is positioned as a leading AI and internet healthcare company, leveraging its smart healthcare ecosystem and strong technological foundation [1] - The collaboration aims to create a comprehensive health management service loop that includes medication guidance, reminders, effect tracking, and health education [1] - The initiative focuses on transforming diabetes and obesity management from a "disease-centered" approach to a "health-centered" model, providing patients with higher quality and more convenient one-stop services [1]